RxDoctor Payments Data

Rhoda Berger

Psychiatric/Mental Health · Brooklyn, NYNPI 1457447559

Payments from drug & device makers

$964in general payments, 2019–2025

Across 31 payments — averaging $31.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$484
  • Neurocrine Biosciences, Inc.$149
  • Lundbeck LLC$145
  • Vanda Pharmaceuticals Inc.$125
  • E.r. Squibb & Sons, L.L.C.$23
  • Johnson & Johnson$19
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$964 in reported general payments places this provider in the 65th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$36,161
Medicare patients
40
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$34,059
LatudaLurasidone Hcl13$30,254
TrintellixVortioxetine Hydrobromide11$8,432
Clozapine140$5,185
Divalproex Sodium118$1,917
Fluvoxamine Maleate50$1,855
Desvenlafaxine ErDesvenlafaxine11$1,612
Quetiapine Fumarate148$1,261
Asenapine Maleate13$1,200
Paliperidone ErPaliperidone13$1,058
Aripiprazole63$906
Bupropion XlBupropion Hcl78$833
Benztropine Mesylate101$665
Carbamazepine ErCarbamazepine23$615
Mirtazapine66$607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$484$34,05924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →